Novartis Venture Fund has helped seed a T-cell drug developer founded from Seattle Children's Hospital, Benaroya Research Institute and MIGAL Galilee.

Stanford-StartX Fund has backed the electronics manufacturing management software developer, with the proceeds going to product development.

Drug protein discovery company Bright Peak hopes to deliver conjugated cancer immunotherapies based on an ETH Zürich-invented platform.

Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.

IU Philanthropic Venture Fund returned for a series A round expected to help MBX identify clinical-stage peptides for rare endocrine genetic diseases.

Vesigen has attracted Leaps by Bayer to commercialise drug delivery technology invented by Quan Lu at Harvard School of Public Health.

Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the Basel spinout.

MIT-founded biochemical water treatment company Solugen has increased its funding total to at least $48.7m.

Neurodegenerative disease company Transquis has emerged from stealth with $30m in series A funding to advance research conducted at Stanford.

Lundbeckfonden Ventures took a board seat at Leiden spinout VarmX as part of a round that will fund development of a treatment for spontaneous bleeding.